An observational study in Arthrogryposis Multiplex Congenita and Piezo2 Mutation Gain of Function, sponsored by University Hospital, Grenoble. Not yet recruiting at 1 site in France. Open to participants aged 10 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by University Hospital, Grenoble · Observational
Study type: Observational, non-interventional, single-center, descriptive study.
Goal of the study:
The goal of this observational study is to characterize the intensity, variability, and qualitative features of pain in patients with arthrogryposis multiplex congenita (AMC) caused by a gain-of-function mutation in PIEZO2. This population is rare and identified through the French national PARART registry (Pediatric and Adult Registry for patients with ARThrogryposis).
Population:
Participants are ≥10 years old, have a genetically confirmed gain-of-function PIEZO2 variant, and are registered in PARART. All procedures are conducted remotely; no onsite visit is required.
Main questions the study aims to answer:
Study design:
There is no comparison group. The study is descriptive and aims to characterize the pain phenotype linked to PIEZO2 gain-of-function mutations.
What participants will do:
Participants will complete the following tasks remotely:
At Day 1:
Questionnaires:
For 14 consecutive days (Day 1 to Day 14), on a paper logbook:
All data are collected through REDCap and a paper logbook. No clinical exam, biological sampling, or hospital visit is required.
The study duration for each participant is 14 days.
Arthrogryposis multiplex congenita (AMC; Orpha code 1037) is a clinically and genetically heterogeneous group of disorders defined by congenital joint contractures affecting at least two distinct body regions (Dahan-Oliel et al. 2019).
Its estimated prevalence ranges from 1 in 3,000 to 1 in 12,000 live births, based on population-based epidemiological studies (Darin et al. 2002; Lowry et al. 2010; Hoff et al. 2012). The pathophysiology of AMC is closely linked to impaired fetal movement, with the severity of musculoskeletal manifestations depending on the timing and degree of fetal akinesia during development (Pollard, McGonnell, and Pitsillides 2014; Nowlan 2015; Felsenthal and Zelzer 2017).
Advances in molecular genetics have identified gain-of-function variants in the mechanosensitive ion channel PIEZO2 as a key etiology in a distinct subgroup of distal arthrogryposis (Coste et al. 2013). PIEZO2 plays a central role in mechanotransduction, converting mechanical stimuli into ionic currents in peripheral sensory neurons, thereby mediating proprioception and mechanical nociception (Wu, Lewis, and Grandl 2017; Szczot et al. 2021; Ma et al. 2023; Sánchez-Carranza et al. 2024).
Structural studies have shown that PIEZO2 forms a large trimeric propeller-shaped mechanosensitive channel whose architecture enables rapid transduction of membrane tension into cation influx, particularly Na⁺ and Ca²⁺ (Wang et al. 2019). Experimental data indicate that PIEZO2 gain-of-function mutations lead to delayed channel inactivation, neuronal hyperexcitability, and aberrant mechanotransduction, which likely underlie the distinctive pain phenotype observed in affected patients (Coste et al. 2013).
Clinically, individuals with PIEZO2-related AMC frequently report chronic diffuse pain with episodic exacerbations that are often poorly responsive to conventional analgesic strategies. Despite this recognizable pattern, genotype-phenotype correlations and the mechanisms driving pain severity and distribution remain insufficiently characterized.
This single-center, non-interventional observational study aims to describe the pain phenotype of individuals with AMC caused by gain-of-function variants in PIEZO2 identified through the national PARART registry (NCT05673265).
The study consists of prospective remote collection of self-reported outcomes using validated questionnaires. On Day 1, participants complete assessments of pain quality (QDSA) and quality of life (SF-12 and EQ-5D-5L), along with documentation of prior analgesic strategies. From Day 1 to Day 14, participants record daily pain intensity using a Numerical Rating Scale (0-100) and pain localization on a body chart, enabling evaluation of pain intensity, temporal variability, and anatomical distribution.
The study relies exclusively on descriptive statistical analyses, without hypothesis testing or comparison groups. Data are collected and managed using REDCap, in accordance with predefined procedures for pseudonymization, data integrity, and regulatory compliance (Harris et al. 2009; Harris et al. 2019). By systematically characterizing pain features and their impact on quality of life, this study seeks to improve understanding of the clinical pain profile associated with PIEZO2 gain-of-function mutations and to provide a foundation for future mechanism-based therapeutic strategies in this rare condition.
Patients affected by Arthrogryposis Multiplex Congenita with mutation gain of function of Piezo2 gene, followed by the University Hospital of Grenoble.
Exclusion Criteria:
- Age \< 10 years
Numeric Rating Scale
Quantitative Pain Evaluation : scale from 0 (no pain) to 100 (worst pain ever).
Time frame: From the start to the end of the follow-up at 14 days
Body Pain Map
Location of the pain on the body.
Time frame: From the start to the end of the follow-up at 14 days
EuroQol 5-Dimensions 5-Levels
Self-questionnaire to evaluate the quality of life. 5D : Five Dimensions (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/Depression). 5L : Five Levels (No problems, Slight, Moderate, Severe, Extreme problems)
Time frame: At the start of the follow-up (Day 1).
12-Item Short Form Health Survey
The SF-12 is a self-reported questionnaire that produces two summary scores: the Physical Component Summary (PCS) and the Mental Component Summary (MCS).
Time frame: At the start of the follow-up (Day 1).
Saint-Antoine Pain Questionnaire
Qualitative description of pain with a variety of words refering to the different pain types, in distinct groups.
Time frame: At the start of the follow-up (Day 1).
Pain Monitoring / Treatments
Listing of pain treatments (medicinal or non-medicinal) used by the patient.
Time frame: At the start of the follow-up (Day 1).
Plan to share: No — Individual participant data will not be shared due to ethical and regulatory constraints, and because no data-sharing plan is defined in the study protocol.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Grenoble